The drug combination is part of the Almirall respiratory franchise that AZ took over earlier this month, paying $875 million upfront, and up to a further $1.22 billion in development, launch and ...

Patients with COPD often experience chronic cough, difficulty breathing, and reduced lung function. While the respiratory disease is not curable, it can be treated and managed with medications ...

The drug was administered twice-daily using a nebuliser as a chronic maintenance therapy for people with COPD in the ENHANCE ... must surely now be on the hit-list of potential takeover targets.

PharmD Inhalers for chronic obstructive pulmonary disease (COPD) are a mainstay of treatment. These medications are inhaled through your mouth so they can directly reach your lungs. If your ...

and routinization of drug therapy are critical for optimal medication adherence in patients with COPD.

using National Drug Codes for anticholinergics, beta-agonists, and combination medications, and number of days covered by ≥1 COPD medication divided by total number of days. Variables were ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type ...

but the Food and Drug Administration’s approval of the drug for chronic obstructive pulmonary disease greatly expands its reach — and could give it an edge over rival treatments in development.

knowledge about and faith in the treatment, effective patient-clinician interaction, and routinization of drug therapy are critical for optimal medication adherence in COPD patients.

Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA). The drug ...

GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab ... stage studies for COPD. GSK has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks ...